https://www.marketscreener.com/quote/stock/INNOVATION-PHARMACEUTICAL-111313705/news/Cellceutix-Phase-2-Brilacidin-Trial-Progresses-to-Highest-Dose-Cohort-for-the-Induction-of-Remission-23924425/?utm_source=telegram&utm_medium=social&utm_campaign=share